Endogena is very pleased to announce that Dr. Moreno Menghini was appointed as CMO. Dr. Menghini is a vitreoretinal surgeon with clinical trial experience in retinal degeneration and will lead Endogena’s upcoming clinical studies.
“I am very excited to be part of the pioneering team at Endogena, and as such be at the forefront of medical innovation.” Dr. Menghini says.